• Work with us
  • External Contractors
Fondazione Toscana Life Sciences
  • IT
  • EN
Toscana Life Sciences
  • THE FOUNDATION
    • Organization
    • History
    • Membership
    • The Legislative Decree No. 231/2001
  • Activity
  • Cluster
  • ITS VITA
  • BIOINCUBATOR
    • Join the Bioincubator
    • Incubated companies
    • Research groups
    • Affiliated companies
  • Services
    • Business development services
    • Research services
    • Incubation services
    • Protection of intellectual property
  • Projects
    • Advanced ERC Grant OMVac
    • Advanced ERC Grant vAMRes
    • Regions4PerMed
    • COSME-AI4DIAG
    • IDF SHARID
  • Disseminating
    • TLS Open Doors
    • Scientists for a day
    • Science + Economy = Business
    • Researcher’s Night
    • European Biotech Week
  • Orphan diseases
  • Stories
Enter any keyword and press enter

Advanced ERC Grant vAMRes

  • Projects
    • Advanced ERC Grant OMVac
    • Advanced ERC Grant vAMRes
    • Regions4PerMed
    • COSME-AI4DIAG
    • IDF SHARID

ERC Advanced Grant – “Isolation and screening of human monoclonal antibodies against AMR for therapy and for discovery of novel vaccine antigens”


General aspects
The reasearch project aims at producing vaccines able to contrast antibiotic bacterial resistance. The project will last 5 years and represents one of the most important scientific challenges of our time, financed with 2,5 million euros. The project, led by Dr. Rino Rappuoli, a pioneer in the vaccine field, obtained an European Research Council (ERC) Advanced Grant and will be realised in cooperation with Toscana Life Sciences Foundation (TLS) as “host institution”. TLS will provide for laboratories, technology platforms and expertise inside an innovative and stimulating environment.

Research activities
“Isolation and screening of human monoclonal antibodies against AMR for therapy and for discovery of novel vaccine antigens” aims, through isolation of natural antibodies and identification of the recognised antigens, at developing vaccines able to defeat Neisseria gonorrhoeae (Gonococcus), Streptococcus pneumoniae (Pneumococcus) and Escherichia coli pathogenic strains. How? Through the application of advanced technologies to reverse vaccinology developed by Rino Rappuoli at the end of ‘90s and now proposed again with a 2.0 approach. The idea, based on the completely sequenced genomes of pathogenic bacteria, allowed, in the last 20 years, the development of vaccines once very difficult to produce. Today, with the new high throughput cloning, sequencing and screening platforms, new opportunities are opened to contrast antimicrobial resistance, a phenomenon which causes, according with the WHO, about 700,000 deceases per year with a forecast for 2050 of more than 10 million deaths, even more than those caused nowadays by cancer.


Contacts:

Cristina Tinti
c.tinti@toscanalifesciences.org


Principal Investigator: Rino Rappuoli

Scientific Advisory Board (SAB):
Oretta Finco
Mariagrazia Pizza
Isabel Delany
Aldo Tagliabue

Research Group:
Marco Troisi m.troisi@toscanalifesciences.org

Emanuele Andreano e.andreano@toscanalifesciences.org

Claudia Sala c.sala@toscanalifesciences.org

Fondazione Toscana Life Sciences
Via Fiorentina, 1
53100 Siena – ITALIA

  • tel +39 0577 231211
  • fax +39 0577 43444
  • info@toscanalifesciences.org; info@pec.fondazionetls.org

Twitter Feeds

🕵️‍♀️Cerchiamo talenti. Scopri le nostre offerte di lavoro e consulta, direttamente online, le posizione aperte pre…

@FondazioneTLS 2 Days Ago

🗣Una rete di relazioni sempre più solida💪 📈Dal 2007 a oggi le imprese incubate e affiliate insieme ai gruppi di ric…

@FondazioneTLS 4 Days Ago

🗣Se hai esperienza nel Project Management e sei alla ricerca di una nuova sfida professionale unisciti al Project M…

@FondazioneTLS 6 Days Ago

Contatti

    Concedo il consenso al trattamento dei dati personali secondo la nostra Privacy Policy per poter essere contattato da Fondazione Toscana Life Sciences.

©2015-2019 - Fondazione Toscana Life Sciences - P.I. 01194710529 - Codice SDI: SUBM70N - Privacy - Cookie Policy